Author

M. A. Munoz-Alia

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Organism:non-human primate· 1 Assay:proteomics· 1

Frequent Co-Authors

A. Baum· 1 shared A. Jaochimiak· 1 shared B. Balakrishnan· 1 shared B. C. Dickinson· 1 shared B. C. Mounce· 1 shared B. Schuster· 1 shared C. A. Kyratsous· 1 shared C. B. Brooke· 1 shared

Activity by Year

2020-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

A. Baum

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

ImmunologyVaccinePeer-reviewedApr 1, 2022

Boosting of SARS-CoV-2 immunity in nonhuman primates using an oral rhabdoviral vaccine

K. W. Peng, T. Carey, P. Lech…·S. J. Russell

This study develops an oral rhabdoviral vaccine that boosts SARS-CoV-2 immunity in nonhuman primates by enhancing viral tropism through G protein trans-complementation.

DOI 10.1016/j.vaccine.2021.12.063

non-human primateexperimental assay

𝕏 PostBluesky

MicrobiologybioRxivAug 31, 2020

Drug repurposing screen identifies masitinib as a 3CLpro inhibitor that blocks replication of SARS-CoV-2 in vitro

N. Drayman, K. A. Jones, S.-A. Azizi…·S. Tay

The paper screens 1,900 drugs to find inhibitors of SARS-CoV-2 replication, identifies masitinib as a 3CLpro inhibitor effective in vitro, and shows its broad anti-viral activity.

DOI 10.1126/science.abg5827

humanproteomics

𝕏 PostBluesky